a public good project by the
Synthesis
Company
of California

© 2026

Tadeusz Pieńkowski | doi.page

0 works0 citations0 h-index

Tadeusz Pieńkowski

Radom College(PL)Postgraduate School of Molecular Medicine(PL)

Publications by Year

Research Areas

HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, PI3K/AKT/mTOR signaling in cancer

Most-Cited Works

→ Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer(2006)3,443 cited
→ Adjuvant Trastuzumab in HER2-Positive Breast Cancer(2011)2,750 cited
→ Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer(2011)2,495 cited
→ Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial(2011)2,312 cited
→ Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial(2012)2,016 cited
→ Adjuvant Docetaxel for Node-Positive Breast Cancer(2005)951 cited

→ Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98(2007)901 cited

→ 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial(2016)852 cited

→ A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses(2008)802 cited

→ Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study(2005)664 cited